30 closest matches · ranked by relevance
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
AML
Primary: Complete Response Rate — 19 Participants
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Relapsed/Refractory Acute Myeloid Leukemia
Primary: Count of Patients With Treatment-Emergent Adverse Events (Phase 1) — 6 Participants
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: The Rate of Complete Remission (CR+CRi) — 0.143; 0.278; 0.15 proportion of participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Primary: Participants With a Response — 3 Participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Recurrent Acute Myeloid Leukemia · Recurrent Chronic Myelomonocytic Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Participants With a Response — 2; 2 Participants
Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Number of Participants With a Response of CR, CRp, or PR — 0; 1; 0 participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia
Primary: Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado) — 400 mg/m^2
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities of MLN4924 (Pevonedistat) — 1; 2 Participants
Leukemia
Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Acute Myeloid Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Maximum Tolerated Dose of Clofarabine — 25 mg/m^2 of clofarabine
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Primary: Maximum Tolerated Dose of 5-azacytidine in the Combination of Nivolumab With Dihydro-5-azacytidine — 75; 75; 75 Mg/m^2
Acute Myelogenous Leukemia
Primary: Overall Survival - Overall and by Calculated Strata (CSR 7-April-11) — 6.6; 6.4; 5.1; 5.5 months — p=0.9951
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Participants With a Response — 4; 9; 16; 2 participants
Leukemia, Myeloid
Primary: Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International…
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Leukemia, Acute Myeloid (AML)
Primary: Duration of Overall Survival (OS) — 9.3; 5.6 Months — p=0.0004
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Primary: Complete Remission (CR) — 0; 0 Participants
Granulocytic Sarcoma · Recurrent Adult Acute Myeloid Leukemia
Primary: Feasibility of Administering CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone During Induction, Consolidation and Maintenance Therapies, Defined as…
Acute Myeloid Leukemia
Primary: Summary of Best Modified Criteria Response Results, Bridged-to-Transplant (BTT) Participants, and Composite Remission Rates in Patients on Treatment With PLX3397 (Dose…